J Gynecol Oncol.  2009 Jun;20(2):101-106. 10.3802/jgo.2009.20.2.101.

Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer

• Bae J
• Lim MC
• Choi JH
• Song YJ
• Lee KS
• Kang S
• Seo SS
• Park SY

• KMID: 2245092
• DOI: http://doi.org/10.3802/jgo.2009.20.2.101

Abstract

OBJECTIVE
The objective of this study was to identify the prognostic factors of secondary cytoreductive surgery on survival in patients with recurrent epithelial ovarian cancer.
METHODS
The medical records of all patients who underwent secondary cytoreductive surgery between May 2001 and October 2007 at the National Cancer Center, Korea were reviewed. Univariate and multivariate analyses were executed to evaluate the potential variables for overall survival.
RESULTS
In total, 54 patients met the inclusion criteria. Optimal cytoreduction to <0.5 cm residual disease was achieved in 87% of patients who had received secondary cytoreductive surgery. Univariate analysis revealed that site of recurrence (median survival, 53 months for the largest tumors in the pelvis vs. 24 months for the largest tumors except for the pelvis; p=0.007), progression free survival (PFS) (median survival, 43 months for PFS> or =12 months vs. 24 months for PFS<12 months; p=0.036), and number of recurrence sites (median survival, 49 months for single recurred tumor vs 29 months for multiple recurred tumors; p=0.036) were significantly associated with overall survival. On multivariate analysis, prognostic factors that correlated with improved survival were site of recurrence (p=0.013), and PFS (p=0.043).
CONCLUSION
In the author's analysis, a significant survival benefit was identified for the recurred largest tumors within the pelvis and PFS> or =12 months. Secondary cytoreductive surgery should be offered in selected patients and large prospective studies are needed to define the selection criteria for secondary cytoreductive surgery.

Keyword

Secondary cytoreductive surgery; Recurrent ovarian cancer; Prognostic factor

MeSH Terms

Disease-Free Survival
Humans
Korea
Medical Records
Multivariate Analysis
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Patient Selection
Pelvis
Recurrence
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms

Figure

• 

  Fig. 1 Overall survival according to the site of recurrence.

• 

  Fig. 2 Overall survival according to progression free survival. PFS: progression free survival

Reference

1. Burke TW, Morris M. Secondary cytoreductive surgery for ovarian cancer. Obstet Gynecol Clin North Am. 1994. 21:167–178.

2. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975. 42:101–104.

3. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002. 20:1248–1259.

4. Chen LM, Karlan BY. Recurrent ovarian carcinoma: is there a place for surgery? Semin Surg Oncol. 2000. 19:62–68.

5. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000. 88:144–153.

6. Ayhan A, Gultekin M, Taskiran C, Aksan G, Celik NY, Dursun P, et al. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Obstet Gynecol. 2006. 194:49–56.

7. Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol. 1983. 61:189–193.

8. Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol. 1993. 11:434–439.

9. Zang RY, Zhang ZY, Li ZT, Chen J, Tang MQ, Liu Q, et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol. 2000. 75:24–30.

10. Munkarah A, Levenback C, Wolf JK, Bodurka-Bevers D, Tortolero-Luna G, Morris RT, et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol. 2001. 81:237–241.

11. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2001. 83:504–512.

12. Tay EH, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol. 2002. 99:1008–1013.

13. Zang RY, Li ZT, Tang J, Cheng X, Cai SM, Zhang ZY, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. 2004. 100:1152–1161.

14. Onda T, Yoshikawa H, Yasugi T, Yamada M, Matsumoto K, Taketani Y. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer. 2005. 92:1026–1032.

15. Gungor M, Ortac F, Arvas M, Kosebay D, Sonmezer M, Kose K. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol. 2005. 97:74–79.

16. Gronlund B, Lundvall L, Christensen IJ, Knudsen JB, Hogdall C. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur J Surg Oncol. 2005. 31:67–73.

17. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006. 106:1933–1939.

18. Tebes SJ, Sayer RA, Palmer JM, Tebes CC, Martino MA, Hoffman MS. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2007. 106:482–487.

19. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004. 95:273–280.

20. Salani R, Santillan A, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Armstrong DK, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007. 109:685–691.